NEJM publishes the CIRT trial - Methotrexate given to stable atherosclerosis patients for nearly 3 years was equal to placebo in the prevention of cardiovascular outcomes (MI, CVA, death, unstable angina). Story covered on RheumNow https://t.co/YCdwzKD9Da